BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pucci P. Combination therapy and noncoding RNAs: a new era of cancer personalized medicine. Epigenomics 2021. [PMID: 34852634 DOI: 10.2217/epi-2021-0405] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Pucci P, Lee L, Han M, Matthews J, Jahangiri L, Manners E, Sorby-adams A, Schlederer M, Kaggie J, Trigg R, Prokoph N, Ducray S, Merkel O, Rifatbegovic F, Luo J, Taschner-mandl S, Kenner L, Burke G, Turner S. Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers collateral sensitivity to ALK inhibitors in high-risk neuroblastoma.. [DOI: 10.21203/rs.3.rs-2167328/v1] [Reference Citation Analysis]
2 Pandey M, Wen PX, Ning GM, Xing GJ, Wei LM, Kumar D, Mayuren J, Candasamy M, Gorain B, Jain N, Gupta G, Dua K. Intraductal delivery of nanocarriers for ductal carcinoma in situ treatment: a strategy to enhance localized delivery. Nanomedicine (Lond) 2022;17:1871-89. [PMID: 36695306 DOI: 10.2217/nnm-2022-0234] [Reference Citation Analysis]